Imricor Medical Systems (ASX:IMR): US Commercial Launch and Clinical Progress

Aditi Sarkar

20 October 2026 04:53 PM AEDT

Imricor Medical Systems (ASX:IMR): US Commercial Launch and Clinical Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Imricor Medical Systems (ASX:IMR) commenced its US commercial rollout with a first hospital customer.
The June 2026 quarter delivered revenue of US$60,500 and a net loss of approximately US$7.4 million.
Operating cash outflows were US$6.1 million, compared with US$7.9 million in the preceding quarter.
FDA paediatric clearances and an MRI laboratory collaboration expanded the company’s commercial scope.

Imricor Medical Systems, Inc. (ASX:IMR) develops equipment, software and single-use medical devices for cardiac procedures performed under real-time magnetic resonance imaging (MRI) guidance. Its 2026 activities have centred on regulatory clearance, clinical trials and the beginning of commercial sales in the United States. On 20 October 2026, Imricor traded at AUD 1.385, down 1.07% during the session. Separate from that market quotation, recent company disclosures describe a new US hospital customer, an expanded product pathway and ongoing expenditure on commercial development.

Company Business

Imricor designs systems for interventional MRI laboratories, where clinicians can undertake selected cardiac catheter-based procedures using magnetic resonance guidance instead of conventional X-ray fluoroscopy. Its NorthStar platform supports three-dimensional mapping and catheter guidance; the Vision-MR range includes diagnostic and ablation catheters. Advantage-MR provides electrophysiology recording and stimulation capabilities. The business combines equipment installations with sales of procedure-related consumables and software.

Commercial activities span Europe and the emerging US market, with regulatory authorisations and clinical programmes determining which products and procedures are available in each jurisdiction. Imricor (ASX:IMR) also works with MRI equipment providers because hospital adoption depends on equipment compatibility, workflow integration and clinical training. Its technology addresses specialised cardiac procedures rather than the wider diagnostic imaging market.

Recent Development

In September 2026, Rady Children’s Hospital–San Diego was announced as Imricor’s first commercial US hospital customer. The hospital is establishing a NorthStar-guided cardiac catheterisation programme using an interventional MRI laboratory. The announcement followed the August launch of Imricor Cardiovascular, a business initiative dedicated to MRI-guided catheterisation procedures in the United States. The company did not disclose a completed nationwide rollout.

In July, the US Food and Drug Administration cleared paediatric use of NorthStar and the Vision-MR Diagnostic Catheter. These clearances cover the specified devices and should not be confused with approval of the ablation catheter, which follows a separate premarket approval process. Imricor (ASX:IMR) submitted the third module of its ablation catheter application and stated that the remaining module depends on completion of the VISABL-AFL trial.

A separate August announcement described a cardiac interventional MRI laboratory solution developed with Philips, combining its 1.5-tesla MRI platform with Imricor systems and consumables. Compatibility testing and installation remain important practical elements of hospital deployment. The VISABL-VT programme also continued at Amsterdam University Medical Centre, while VISABL-AFL enrolment proceeded at sites in the United States and Europe.

Financial Performance and Sector Context

For the quarter ended 30 June 2026, Imricor (ASX:IMR) reported revenue of US$60,500, compared with US$65,200 for the corresponding quarter. The company explained that consumables used in certain clinical-trial procedures were not recognised as sales revenue. Quarterly net loss was approximately US$7.4 million, against US$7.8 million in the comparable period. These figures reflect a business still funding product development, clinical studies and its commercial network.

Net operating cash used in the June quarter totalled US$6.1 million, compared with US$7.9 million in the March quarter. Cash and short-term investments stood at US$67.5 million on 30 June 2026. Subsequently exercised options provided approximately US$2.1 million, resulting in an indicated pro forma funding position of US$69.6 million at that date. Imricor also reported completing an A$60 million placement in 2026.

The relevant medical-device sector is shaped by hospital procurement decisions, regulatory requirements, clinician training and evidence from clinical trials. Regulatory clearance for one indication or device does not establish approval for every clinical application. For Imricor (ASX:IMR), commercial equipment sales and recurring procedure demand therefore depend on separate adoption stages.

Risks to Consider

Clinical recruitment or regulatory review delays could postpone further US product availability. Hospital capital budgets, installation schedules, equipment compatibility and staff training may affect the timing of sales. International activity introduces reimbursement, distribution and regulatory differences. Continued cash expenditure is another consideration while revenue remains limited relative to operating costs. The company has also identified uncertainty around sales and clinical activity in parts of the Middle East.

What to Watch Next

Operational disclosures may clarify when the first US NorthStar installations begin clinical activity and whether additional hospital purchases proceed. Updates to the VISABL-AFL enrolment timetable and the final ablation-catheter submission will also be relevant. Imricor (ASX:IMR) may report progress with MRI-platform compatibility, European site conversions and the expansion of its US sales organisation. Subsequent quarterly filings will show revenue recognition, spending and available cash.

Key Insights

Imricor Medical Systems (ASX:IMR) entered a new commercial phase in 2026 through US device clearances, a first American hospital customer and expanded MRI-laboratory compatibility. June-quarter revenue remained small against clinical and commercial expenditure, although its reported funding position provided resources for continued operations. The key measurable developments are hospital installations, regulatory milestones, clinical enrolment, product sales and cash flows; none is established by a single day’s share-price movement.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.